Boca Raton, FL - David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT) today announced that a poster presentation of a study confirming the predictive value of the Company's PD2i® nonlinear algorithm and software for cardiac mortality made during the recent American College of Cardiology 60th Annual Scientific Session garnered interest from researchers and clinicians. Researchers attending the poster presentation expressed interest in using the Company's PD2i® nonlinear algorithm and software in new studies with the goal of determining its applicability for other cardiovascular disease states. Clinicians queried Company representatives about its use in the clinical setting. Vicor Technologies is a biotechnology company focused on the commercialization of its PD2i Analyzer™, an innovative, non-invasive diagnostic employing its patented, proprietary PD2i® nonlinear algorithm. Physician use of the PD2i Analyzer™ is supported by an expanding body of literature demonstrating the value of the PD2i® nonlinear algorithm as a metric for risk stratifying specific target populations for future pathological events, including diabetics for the presence of diabetic autonomic neuropathy (DAN), cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, and trauma victims for imminent death absent immediate lifesaving intervention.

The poster presentation -- "Prognostic Significance of PD2i, Novel Risk Marker in Heart Failure Patients" - was made by Wojciech Zareba, MD, PhD, Professor of Medicine, Director of Cardiology Clinical Research, and Director of the Heart Research Follow-up Program at the University of Rochester Medical Center. The presentation, made on April 4, 2011, is based on a study titled "Prognostic Significance of Point Correlation Dimension Algorithm (PD2i) in Chronic Heart Failure," which was conducted under a collaborative agreement between Vicor Technologies, and the University of Rochester and the Catalan Institute of Cardiovascular Sciences in Barcelona. Dr. Zareba was the Principal Investigator on that study. Commenting on the study results, Dr. Zareba said, "These results are of major importance for risk stratifying heart failure patients who are eligible for therapy with an implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy with defibrillator (CRT-D). Testing heart failure patients using the PD2i® should enhance risk stratification and motivate physicians to implant these devices in ICD/CRT-D eligible patients with abnormal PD2i® test results."

More HCB News